Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors.
Aminoguanidine decreases the formation of advanced glycosylation end products that occurs during chronic hyperglycemia. Presumably this occurs because early glycosylation products preferentially bind to aminoguanidine rather than to lysine groups of adjacent proteins. Because oxidative modification...
Furkejuvvon:
| Publikašuvnnas: | Proc Natl Acad Sci U S A |
|---|---|
| Váldodahkkit: | , , , |
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
National Academy of Sciences
1992
|
| Fáttát: | |
| Liŋkkat: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC49607/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1495978/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.89.15.6876 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|